{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T10:15:42Z","timestamp":1773915342519,"version":"3.50.1"},"reference-count":149,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T00:00:00Z","timestamp":1636588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Patients with CD5-expressing lymphomas presenting with splenomegaly are frequently diagnosed with chronic lymphocytic leukemia. The most important differential diagnosis is mantle cell lymphoma, both in its classical and leukemic, non-nodal forms, given its prognostic and therapeutic implications. Other small B-cell neoplasms that frequently involve the spleen and occasionally express CD5 include the splenic marginal zone lymphoma, hairy cell leukemia and, rarely, lymphoplasmacytic lymphoma. The frequency of CD5 positivity depends in part on the sensitivity of the detection methods employed. Usually, a combination of morphological, immunophenotypic and molecular findings allows for a precise sub-classification of CD5-positive, low-grade B-cell lymphomas of the spleen. Some of these tumors may display a mixture of small and larger B cells, raising the possibility of more aggressive lymphomas, such as diffuse large B-cell lymphomas (DLBCL). Approximately 5\u201310% of DLBCL are CD5-positive and some may manifest as primary splenic lesions. When available, the morphology of DLBCL in the splenic tissue is distinctive and a leukemic picture is very rare. In conclusion, the appropriate morphological and clinical context assisted by flow cytometry panels and\/or immunohistochemistry allows the differential diagnosis of CD5-positive, non-Hodgkin, B-cell lymphomas involving the spleen.<\/jats:p>","DOI":"10.3390\/curroncol28060390","type":"journal-article","created":{"date-parts":[[2021,11,11]],"date-time":"2021-11-11T23:02:41Z","timestamp":1636671761000},"page":"4611-4633","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["How to Diagnose and Treat CD5-Positive Lymphomas Involving the Spleen"],"prefix":"10.3390","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6232-1596","authenticated-orcid":false,"given":"Jos\u00e9","family":"Cabe\u00e7adas","sequence":"first","affiliation":[{"name":"Department of Pathology, Portuguese Institute of Oncology Lisbon, 1099-023 Lisboa, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victor E.","family":"Nava","sequence":"additional","affiliation":[{"name":"Department of Pathology, The George Washington University, Washington, DC 20037, USA"},{"name":"Department of Pathology, Veterans Health Administration Medical Center, Washington, DC 20422, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joao L.","family":"Ascensao","sequence":"additional","affiliation":[{"name":"School of Medicine, The George Washington University, Washington, DC 20037, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6993-2450","authenticated-orcid":false,"given":"Maria","family":"Gomes da Silva","sequence":"additional","affiliation":[{"name":"Department of Hematology, Portuguese Institute of Oncology Lisbon, 1099-023 Lisboa, Portugal"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2021,11,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1053\/j.semdp.2020.08.002","article-title":"B-Cell Neoplasms and Hodgkin Lymphoma in the Spleen","volume":"38","author":"Geyer","year":"2021","journal-title":"Semin. Diagn. Pathol."},{"key":"ref_2","unstructured":"Swerdlow, S., Campo, E., Harris, N., Jaffe, E., Pileri, S., Stein, H., and Thiele, J. (2017). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC. [4th ed.]."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1182\/blood-2010-09-271437","article-title":"How I Diagnose and Treat Splenic Lymphomas","volume":"117","author":"Iannitto","year":"2011","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1053\/j.seminhematol.2018.05.007","article-title":"Diagnosis and Classification of Lymphoma: Impact of Technical Advances","volume":"56","author":"Jaffe","year":"2019","journal-title":"Semin. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1080\/16078454.2019.1591570","article-title":"Diagnostic and Therapeutic Splenectomy for Splenic Lymphomas: Analysis of the National Cancer Data Base","volume":"24","author":"Fallah","year":"2019","journal-title":"Hematology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2958","DOI":"10.3889\/oamjms.2019.568","article-title":"Indications for Surgery in Non-Traumatic Spleen Disease","volume":"7","author":"Coco","year":"2019","journal-title":"Open Access Maced. J. Med. Sci."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"655","DOI":"10.2214\/AJR.15.15125","article-title":"Safety and Accuracy of Percutaneous Image-Guided Core Biopsy of the Spleen","volume":"206","author":"Olson","year":"2016","journal-title":"Am. J. Roentgenol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1177\/0846537120903692","article-title":"Percutaneous Image-Guided Biopsy of the Spleen: Experience at a Single Tertiary Care Center","volume":"72","author":"John","year":"2021","journal-title":"Can. Assoc. Radiol. J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/ijlh.13170","article-title":"Flow Cytometry in the Diagnosis of Mature B-Cell Lymphoproliferative Disorders","volume":"42","author":"Debord","year":"2020","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3960\/jslrt.19041","article-title":"Differential Diagnosis of Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma and Other Indolent Lymphomas, Including Mantle Cell Lymphoma","volume":"60","author":"Yoshino","year":"2020","journal-title":"J. Clin. Exp. Hematop."},{"key":"ref_11","first-page":"S35","article-title":"CD5-Positive Chronic B-Cell Lymphoproliferative Disorders: Diagnosis and Prognosis of a Heterogeneous Disease Entity","volume":"78","author":"Dronca","year":"2010","journal-title":"Cytom. Part B-Clin. Cytom."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1182\/blood-2011-04-345256","article-title":"Prognostic Significance of Immunohistochemical Biomarkers in Diffuse Large B-Cell Lymphoma: A Study from the Lunenburg Lymphoma Biomarker Consortium","volume":"117","author":"Salles","year":"2011","journal-title":"Blood"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for Initial Evaluation, Staging, and Response Assessment of Hodgkin and Non-Hodgkin Lymphoma: The Lugano Classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e3750","DOI":"10.1097\/MD.0000000000003750","article-title":"PET-CT for Evaluation of Spleen and Liver 18 F-FDG Diffuse Uptake Without Lymph Node Enlargement in Lymphoma","volume":"95","author":"Rao","year":"2016","journal-title":"Medicine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"IwCLL Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1309\/HWG084N3F3LRJ8XB","article-title":"Histopathologic Features of Splenic Small B-Cell Lymphomas: A Study of 42 Cases With a Definitive Diagnosis by the World Health Organization Classification","volume":"120","author":"Kansal","year":"2003","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1002\/1097-0142(19841015)54:8<1606::AID-CNCR2820540823>3.0.CO;2-5","article-title":"Primary Splenic Presentation of Malignant Lymphoma and Related Disorders. A Study of 49 Cases","volume":"54","author":"Kraemer","year":"1984","journal-title":"Cancer"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Vitale, C., Montalbano, M.C., Salvetti, C., Boccellato, E., Griggio, V., Boccadoro, M., and Coscia, M. (2020). Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs. Cancers, 12.","DOI":"10.3390\/cancers12020282"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1080\/17474086.2018.1489720","article-title":"Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: A Concise Review and Treatment Recommendations","volume":"11","author":"Kater","year":"2018","journal-title":"Expert Rev. Hematol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10875-014-9995-5","article-title":"Antibody Deficiency Secondary to Chronic Lymphocytic Leukemia: Should Patients Be Treated with Prophylactic Replacement Immunoglobulin?","volume":"34","author":"Dhalla","year":"2014","journal-title":"J. Clin. Immunol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1038\/leu.2015.313","article-title":"A Complementary Role of Multiparameter Flow Cytometry and High-Throughput Sequencing for Minimal Residual Disease Detection in Chronic Lymphocytic Leukemia: An European Research Initiative on CLL Study","volume":"30","author":"Rawstron","year":"2016","journal-title":"Leukemia"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1002\/cyto.b.21595","article-title":"Reproducible Diagnosis of Chronic Lymphocytic Leukemia by Flow Cytometry: An European Research Initiative on CLL (ERIC) & European Society for Clinical Cell Analysis (ESCCA) Harmonisation Project","volume":"94","author":"Rawstron","year":"2018","journal-title":"Cytom. Part B-Clin. Cytom."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.3324\/haematol.2011.042333","article-title":"Reassessment of Small Lymphocytic Lymphoma in the Era of Monoclonal B-Cell Lymphocytosis","volume":"96","author":"Gibson","year":"2011","journal-title":"Haematologica"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia","volume":"343","author":"Stilgenbauer","year":"2000","journal-title":"N. Engl. J. Med."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.annonc.2020.09.019","article-title":"Chronic Lymphocytic Leukaemia: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"32","author":"Eichhorst","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/leu.2015.14","article-title":"Obinutuzumab as Frontline Treatment of Chronic Lymphocytic Leukemia: Updated Results of the CLL11 Study","volume":"29","author":"Goede","year":"2015","journal-title":"Leukemia"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"931","DOI":"10.3324\/haematol.2017.186684","article-title":"Morphological, Immunophenotypic, and Genetic Features of Chronic Lymphocytic Leukemia with Trisomy 12: A Comprehensive Review","volume":"103","author":"Autore","year":"2018","journal-title":"Haematologica"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","article-title":"Chronic Lymphocytic Leukaemia: From Genetics to Treatment","volume":"16","author":"Bosch","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","article-title":"Unmutated Ig V(H) Genes Are Associated with a More Aggressive Form of Chronic Lymphocytic Leukemia","volume":"94","author":"Hamblin","year":"1999","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V Gene Mutation Status and CD38 Expression As Novel Prognostic Indicators in Chronic Lymphocytic Leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/leu.2014.252","article-title":"A B-Cell Epigenetic Signature Defines Three Biologic Subgroups of Chronic Lymphocytic Leukemia with Clinical Impact","volume":"29","author":"Villamor","year":"2015","journal-title":"Leukemia"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1182\/bloodadvances.2019000237","article-title":"Clinical Significance of DNA Methylation in Chronic Lymphocytic Leukemia Patients: Results from 3 UK Clinical Trials","volume":"3","author":"Wojdacz","year":"2019","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/leu.2016.322","article-title":"Antigen Receptor Stereotypy in Chronic Lymphocytic Leukemia","volume":"31","author":"Stamatopoulos","year":"2017","journal-title":"Leukemia"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-Genome Sequencing Identifies Recurrent Mutations in Chronic Lymphocytic Leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1182\/blood-2015-07-659144","article-title":"Clinical Impact of Clonal and Subclonal TP53, SF3B1, BIRC3, NOTCH1, and ATM Mutations in Chronic Lymphocytic Leukemia","volume":"127","author":"Nadeu","year":"2016","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1038\/s41375-018-0215-9","article-title":"Clonal Diversity Predicts Adverse Outcome in Chronic Lymphocytic Leukemia","volume":"33","author":"Leeksma","year":"2019","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1182\/asheducation-2017.1.329","article-title":"The Mutational Landscape of Chronic Lymphocytic Leukemia and Its Impact on Prognosis and Treatment","volume":"2017","author":"Gaidano","year":"2017","journal-title":"Hematology"},{"key":"ref_38","doi-asserted-by":"crossref","unstructured":"International CLL-IPI Working Group (2016). An International Prognostic Index for Patients with Chronic Lymphocytic Leukaemia (CLL-IPI): A Meta-Analysis of Individual Patient Data. Lancet Oncol., 17, 779\u2013790.","DOI":"10.1016\/S1470-2045(16)30029-8"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.20.00979","article-title":"Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model","volume":"39","author":"Ahn","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3758","DOI":"10.1200\/JCO.2016.67.1305","article-title":"Minimal Residual Disease Assessment Improves Prediction of Outcome in Patients with Chronic Lymphocytic Leukemia (CLL) Who Achieve Partial Response: Comprehensive Analysis of Two Phase III Studies of the German CLL Study Group","volume":"34","author":"Kovacs","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1182\/blood-2017-06-792333","article-title":"A Model for Predicting Effect of Treatment on Progression-Free Survival Using MRD as a Surrogate End Point in CLL","volume":"131","author":"Dimier","year":"2018","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus Rituximab in Relapsed Chronic Lymphocytic Leukemia: 4-Year Results and Evaluation of Impact of Genomic Complexity and Gene Mutations from the MURANO Phase III Study","volume":"38","author":"Kater","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cell.2019.06.011","article-title":"Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction","volume":"178","author":"Kurtz","year":"2019","journal-title":"Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1186\/s13063-017-2138-6","article-title":"Assessment of Ibrutinib plus Rituximab in Front-Line CLL (FLAIR Trial): Study Protocol for a Phase III Randomised Controlled Trial","volume":"18","author":"Collett","year":"2017","journal-title":"Trials"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib plus Venetoclax in Relapsed\/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and Venetoclax for First-Line Treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3626","DOI":"10.1200\/JCO.20.00491","article-title":"Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Na\u00efve and Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"38","author":"Rogers","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/hon.1_2879","article-title":"Towards Control Of Chronic Lymphocytic Leukemia With Targeted Agents","volume":"39","author":"Hallek","year":"2021","journal-title":"Hematol. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"iv62","DOI":"10.1093\/annonc\/mdx223","article-title":"Newly Diagnosed and Relapsed Mantle Cell Lymphoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann. Oncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1002\/cncr.22715","article-title":"Leukemic Involvement Is a Common Feature in Mantle Cell Lymphoma","volume":"109","author":"Ferrer","year":"2007","journal-title":"Cancer"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00428-020-02750-7","article-title":"Reproducibility of Histologic Prognostic Parameters for Mantle Cell Lymphoma: Cytology, Ki67, P53 and SOX11","volume":"477","author":"Croci","year":"2020","journal-title":"Virchows Arch."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.1182\/blood.V89.6.2067","article-title":"Mantle Cell Lymphoma: A Clinicopathologic Study of 80 Cases","volume":"89","author":"Argatoff","year":"1997","journal-title":"Blood"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1038\/modpathol.2015.99","article-title":"Plasma Cell and Terminal B-Cell Differentiation in Mantle Cell Lymphoma Mainly Occur in the SOX11-Negative Subtype","volume":"28","author":"Martinez","year":"2015","journal-title":"Mod. Pathol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1309\/TE56-A43X-29TT-5H8G","article-title":"CD5\u2014Mantle Cell Lymphoma","volume":"118","author":"Liu","year":"2002","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1309\/AJCPV8LN5ENMZOVY","article-title":"Immunophenotypic Variations in Mantle Cell Lymphoma","volume":"132","author":"Gao","year":"2009","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/PAI.0b013e3181bb9edf","article-title":"BCL6, MUM1, and CD10 Expression in Mantle Cell Lymphoma","volume":"18","author":"Gualco","year":"2010","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/cup.12109","article-title":"CD10-Positive Blastoid Mantle Cell Lymphoma with Secondary Cutaneous Involvement","volume":"40","author":"Phelps","year":"2013","journal-title":"J. Cutan. Pathol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4315","DOI":"10.1182\/blood-2005-04-1753","article-title":"Cyclin D1-Negative Mantle Cell Lymphoma: A Clinicopathologic Study Based on Gene Expression Profiling","volume":"106","author":"Fu","year":"2005","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/PAS.0b013e318241f050","article-title":"Cyclin D1-Negative Blastoid Mantle Cell Lymphoma Identified by SOX11 Expression","volume":"36","author":"Zeng","year":"2012","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.3324\/haematol.2009.010264","article-title":"SOX11 Expression Is Highly Specific for Mantle Cell Lymphoma and Identifies the Cyclin D1-Negative Subtype","volume":"94","author":"Mozos","year":"2009","journal-title":"Haematologica"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1034\/j.1600-0609.2002.01662.x","article-title":"Somatic Hypermutation and VH Gene Usage in Mantle Cell Lymphoma","volume":"68","author":"Walsh","year":"2002","journal-title":"Eur. J. Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"4975","DOI":"10.1182\/blood-2002-06-1864","article-title":"A Subset of t(11;14) Lymphoma with Mantle Cell Features Displays Mutated IgVH Genes and Includes Patients with Good Prognosis, Nonnodal Disease","volume":"101","author":"Orchard","year":"2003","journal-title":"Blood"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1080\/10428190801947559","article-title":"Molecular Genetic Characterization Reveals New Subsets of Mantle Cell Lymphoma","volume":"49","author":"Thelander","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1093\/oxfordjournals.annonc.a059161","article-title":"In Situ Hybridization Detection of Cyclin Dl MRNA in Centrocytic\/Mantle Cell Lymphoma","volume":"6","author":"Williams","year":"1995","journal-title":"Ann. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1182\/blood-2018-07-862151","article-title":"CCND2 and CCND3 Hijack Immunoglobulin Light-Chain Enhancers in Cyclin D12 Mantle Cell Lymphoma","volume":"133","author":"Navarro","year":"2019","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2012-08-452284","article-title":"CCND2 Rearrangements Are the Most Frequent Genetic Events in Cyclin D1\u2014Mantle Cell Lymphoma","volume":"121","author":"Salaverria","year":"2013","journal-title":"Blood"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1200\/JCO.2015.63.8387","article-title":"Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results from Randomized Trials of the European Mantle Cell Lymphoma Network","volume":"34","author":"Hoster","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.hoc.2020.05.002","article-title":"Molecular Pathogenesis of Mantle Cell Lymphoma","volume":"34","author":"Navarro","year":"2020","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3324\/haematol.2011.055715","article-title":"The Impact of Cyclin D1 MRNA Isoforms, Morphology and P53 in Mantle Cell Lymphoma: P53 Alterations and Blastoid Morphology Are Strong Predictors of a High Proliferation Index","volume":"97","author":"Koch","year":"2012","journal-title":"Haematologica"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/j.hoc.2020.06.009","article-title":"Blastoid Mantle Cell Lymphoma","volume":"34","author":"Jain","year":"2020","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjh.14241","article-title":"15-Year Follow-up of the Second Nordic Mantle Cell Lymphoma Trial (MCL2): Prolonged Remissions without Survival Plateau","volume":"175","author":"Eskelund","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1158\/0008-5472.CAN-09-3419","article-title":"Genomic and Gene Expression Profiling Defines Indolent Forms of Mantle Cell Lymphoma","volume":"70","author":"Salamero","year":"2010","journal-title":"Cancer Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"754","DOI":"10.3324\/haematol.2019.219543","article-title":"Highly Sensitive and Specific in Situ Hybridization Assay for Quantification of SOX11 MRNA in Mantle Cell Lymphoma Reveals Association of TP53 Mutations with Negative and Low SOX11 Expression","volume":"105","author":"Federmann","year":"2020","journal-title":"Haematologica"},{"key":"ref_76","first-page":"31","article-title":"Mantle Cell Lymphoma\u2014Advances in Molecular Biology, Prognostication and Treatment Approaches","volume":"39","author":"Silkenstedt","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ctrv.2017.05.008","article-title":"Mantle Cell Lymphoma\u2014Current Standards of Care and Future Directions","volume":"58","author":"Martin","year":"2017","journal-title":"Cancer Treat. Rev."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.hoc.2020.06.008","article-title":"What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?","volume":"34","author":"McCulloch","year":"2020","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(16)00739-X","article-title":"Addition of High-Dose Cytarabine to Immunochemotherapy before Autologous Stem-Cell Transplantation in Patients Aged 65 Years or Younger with Mantle Cell Lymphoma (MCL Younger): A Randomised, Open-Label, Phase 3 Trial of the European Mantle Cell Lymphoma N","volume":"388","author":"Hermine","year":"2016","journal-title":"Lancet"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1056\/NEJMoa1701769","article-title":"Rituximab after Autologous Stem-Cell Transplantation in Mantle-Cell Lymphoma","volume":"377","author":"Thieblemont","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hon.13_2629","article-title":"Autologos Stem Cell Transplantation in First Remissoni Significantly Prolongs Progression-Fre Survival And Overall Survilval in Mantle Cell Lymphoma","volume":"37","author":"Zoellner","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/S1470-2045(18)30685-5","article-title":"Frontline Bortezomib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) versus Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Transplantation-Ineligible Patients with Newly Diagnosed Mantle Cell Lymphoma","volume":"19","author":"Robak","year":"2018","journal-title":"Lancet Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1200\/JCO.19.01294","article-title":"Treatment of Older Patients With Mantle Cell Lymphoma (MCL): Long-Term Follow-Up of the Randomized European MCL Elderly Trial","volume":"38","author":"Hoster","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_84","unstructured":"Salles, G. (2021). Role of Maintenance Rituximab (MR) after First Line (1L) Bendamustine + Rituximab (BR) or R-Chop in Patients (PTS) with Mantle Cell lymphoma (MCL) from A Large US Real-World (RW) Cohor, EHA Library."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1056\/NEJMoa1306220","article-title":"Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"369","author":"Wang","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Phase 2 Study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","article-title":"Ibrutinib versus Temsirolimus in Patients with Relapsed or Refractory Mantle-Cell Lymphoma: An International, Randomised, Open-Label, Phase 3 Study","volume":"387","author":"Dreyling","year":"2016","journal-title":"Lancet"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/S0140-6736(17)33108-2","article-title":"Acalabrutinib in Relapsed or Refractory Mantle Cell Lymphoma (ACE-LY-004): A Single-Arm, Multicentre, Phase 2 Trial","volume":"391","author":"Wang","year":"2018","journal-title":"Lancet"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_90","unstructured":"Rattotti, S., Croci, G., Ferretti, V.V., Morello, L., Marino, D., Carli, G., Ferrero, S., Loseto, G., Olivieri, J., and Pelosini, M. (2017). Mantle Cell Lymphoma Mimicking Mucosa-Associated Lymphoid Tissue (MALT) Lymphomas: A Pathological Characterization (on Behalf of the \"Fondazione Italiana Linfomi (FIL)\u2014Postgraduate Master Course&quot). Blood, 130."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/BF01715382","article-title":"Mantle Cell Lymphoma with the Features of Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma in an HTLV-I-Seropositive Patient","volume":"70","author":"Shibata","year":"1995","journal-title":"Ann. Hematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1002\/ajh.23467","article-title":"Recent Advances in de Novo CD5+ Diffuse Large B Cell Lymphoma","volume":"88","author":"Jain","year":"2013","journal-title":"Am. J. Hematol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"458","DOI":"10.3109\/10428194.2010.540361","article-title":"Cyclin D1 Positive Diffuse Large B-Cell Lymphoma Is a Post-Germinal Center-Type Lymphoma without Alterations in the CCND1 Gene Locus","volume":"52","author":"Adam","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00428-021-03022-8","article-title":"Mantle Cell Lymphomas with Concomitant MYC and CCND1 Breakpoints Are Recurrently TdT Positive and Frequently Show High-Grade Pathological and Genetic Features","volume":"479","author":"Aukema","year":"2021","journal-title":"Virchows Arch."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s11864-019-0684-8","article-title":"Leukemic Non-Nodal Mantle Cell Lymphoma: Diagnosis and Treatment","volume":"20","author":"Jain","year":"2018","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.beha.2019.06.001","article-title":"B and T Cell Prolymphocytic Leukaemia","volume":"32","author":"Cross","year":"2019","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1182\/blood.V89.6.2015","article-title":"P53 Abnormalities in B-Cell Prolymphocytic Leukemia","volume":"89","author":"Lens","year":"1997","journal-title":"Blood"},{"key":"ref_98","first-page":"1821","article-title":"Genetic Characterization of B-Cell Prolymphocytic Leukemia: A Prognostic Model Involving MYC and TP53","volume":"134","author":"Chapiro","year":"2019","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1111\/bjh.15151","article-title":"Idelalisib-Rituximab Induces Durable Remissions in TP53 Disrupted B-PLL but Results in Significant Toxicity: Updated Results of the UK-Wide Compassionate Use Programme","volume":"184","author":"Eyre","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjh.14224","article-title":"Ibrutinib Is an Effective Treatment for B-Cell Prolymphocytic Leukaemia","volume":"179","author":"Gordon","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological Definition of Waldenstrom\u2019s Macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin. Oncol."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/leu.2013.124","article-title":"Multiparameter Flow Cytometry for the Identification of the Waldenstr\u00f6m\u2019s Clone in IgM-MGUS and Waldenstr\u00f6m\u2019s Macroglobulinemia: New Criteria for Differential Diagnosis and Risk Stratification","volume":"28","author":"Paiva","year":"2014","journal-title":"Leukemia"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1053\/sonc.2003.50074","article-title":"Immunophenotypic Analysis of Waldenstrom\u2019s Macroglobulinemia","volume":"30","author":"Vidriales","year":"2003","journal-title":"Semin. Oncol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/annonc\/mdv572","article-title":"Waldenstr\u00f6m\u2019s Macroglobulinemia: A Clinical Perspective in the Era of Novel Therapeutics","volume":"27","author":"Dimopoulos","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P Somatic Mutation in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMc1506192","article-title":"MYD88 Mutations and Response to Ibrutinib in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"373","author":"Treon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1158\/0008-5472.CAN-18-0215","article-title":"MYD88 L265P Mutation in Lymphoid Malignancies","volume":"78","author":"Yu","year":"2018","journal-title":"Cancer Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41375-020-01102-3","article-title":"CXCR4 in Waldenstr\u00f6m\u2019s Macroglobulinema: Chances and Challenges","volume":"35","author":"Kaiser","year":"2021","journal-title":"Leukemia"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/hematology.2020000121","article-title":"Management of Waldenstr\u00f6m Macroglobulinemia in 2020","volume":"20","author":"Castillo","year":"2020","journal-title":"Hematology"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.20.00555","article-title":"Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients with Waldenstr\u00f6m Macroglobulinemia","volume":"39","author":"Treon","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1182\/blood.2019000725","article-title":"How I Treat Waldenstr\u00f6m Macroglobulinemia","volume":"134","author":"Dimopoulos","year":"2019","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/hon.762","article-title":"Nodal and Splenic Marginal Zone B Cell Lymphomas","volume":"23","author":"Mollejo","year":"2005","journal-title":"Hematol. Oncol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1586\/17474086.2013.845522","article-title":"Splenic Marginal Zone Lymphoma: Disease Features and Management","volume":"6","author":"Matutes","year":"2013","journal-title":"Expert Rev. Hematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.annonc.2019.10.010","article-title":"Marginal Zone Lymphomas: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"31","author":"Zucca","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/modpathol.2013.120","article-title":"Hepatitis C Virus-Related Lymphoproliferative Disorders Encompass a Broader Clinical and Morphological Spectrum than Previously Recognized: A Clinicopathological Study","volume":"27","author":"Mollejo","year":"2014","journal-title":"Mod. Pathol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1182\/blood-2013-07-515155","article-title":"Clonal B-Cell Lymphocytosis Exhibiting Immunophenotypic Features Consistent with a Marginal-Zone Origin: Is This a Distinct Entity?","volume":"123","author":"Xochelli","year":"2014","journal-title":"Blood"},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"604","DOI":"10.3324\/haematol.2009.011049","article-title":"CD5 Expression Identifies a Subset of Splenic Marginal Zone Lymphomas with Higher Lymphocytosis: A Clinico-Pathological, Cytogenetic and Molecular Study of 24 Cases","volume":"95","author":"Baseggio","year":"2010","journal-title":"Haematologica"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1111\/bjh.17141","article-title":"Clinical and Biological Features of B-Cell Neoplasms with CDK6 Translocations: An Association with a Subgroup of Splenic Marginal Zone Lymphomas Displaying Frequent CD5 Expression, Prolymphocytic Cells, and TP53 Abnormalities","volume":"193","author":"Gailllard","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1182\/blood-2010-02-267476","article-title":"Cytogenetic Aberrations and Their Prognostic Value in a Series of 330 Splenic Marginal Zone B-Cell Lymphomas: A Multicenter Study of the Splenic B-Cell Lymphoma Group","volume":"116","author":"Salido","year":"2010","journal-title":"Blood"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e310","DOI":"10.3324\/haematol.2016.161711","article-title":"Clinical and Diagnostic Relevance of NOTCH2 and KLF2 Mutations in Splenic Marginal Zone Lymphoma","volume":"102","author":"Cereceda","year":"2017","journal-title":"Haematologica"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1182\/blood-2015-11-624312","article-title":"Splenic Marginal Zone Lymphoma: From Genetics to Management","volume":"127","author":"Arcaini","year":"2016","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1111\/bjh.13320","article-title":"Outcomes in Splenic Marginal Zone Lymphoma: Analysis of 107 Patients Treated in British Columbia","volume":"169","author":"Xing","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1182\/blood-2016-01-689422","article-title":"Consensus Guidelines for the Diagnosis and Management of Patients with Classic Hairy Cell Leukemia","volume":"129","author":"Grever","year":"2017","journal-title":"Blood"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3892\/mco.2020.2142","article-title":"A Rare Case of Hairy Cell Leukemia with Co-Expression of Cd5 and Cyclin D1: A Diagnostic Pitfall","volume":"13","author":"Zhou","year":"2020","journal-title":"Mol. Clin. Oncol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1309\/PMQXVY619Q8Y43AR","article-title":"Immunophenotypic Variations in Hairy Cell Leukemia","volume":"125","author":"Chen","year":"2006","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/his.13206","article-title":"Morphological and Immunophenotypical Features of Hairy Cell Leukaemia Involving Lymph Nodes and Extranodal Tissues","volume":"71","author":"Cortazar","year":"2017","journal-title":"Histopathology"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjh.12839","article-title":"Peripheral Blood 8 Colour Flow Cytometry Monitoring of Hairy Cell Leukaemia Allows Detection of High-Risk Patients","volume":"166","author":"Chandesris","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1111\/bjh.12429","article-title":"BRAF V600E Mutation-Specific Antibody, a Sensitive Diagnostic Marker Revealing Minimal Residual Disease in Hairy Cell Leukaemia","volume":"162","author":"Akarca","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/bjh.12908","article-title":"Long-Term Follow-up and Second Malignancies in 487 Patients with Hairy Cell Leukaemia","volume":"166","author":"Cornet","year":"2014","journal-title":"Br. J. Haematol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.beha.2015.09.004","article-title":"Long-Term Follow-up after Purine Analogue Therapy in Hairy Cell Leukaemia","volume":"28","author":"Else","year":"2015","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/bjh.14129","article-title":"Long-Term Durable Remission by Cladribine Followed by Rituximab in Patients with Hairy Cell Leukaemia: Update of a Phase II Trial","volume":"174","author":"Chihara","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1200\/JCO.19.02250","article-title":"Randomized Phase II Study of First-Line Cladribine with Concurrent or Delayed Rituximab in Patients with Hairy Cell Leukemia","volume":"38","author":"Chihara","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab Pasudotox in Relapsed\/Refractory Hairy Cell Leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJMoa1506583","article-title":"Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia","volume":"373","author":"Tiacci","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"2847","DOI":"10.1182\/blood-2015-11-680074","article-title":"BRAF Inhibition in Hairy Cell Leukemia with Low-Dose Vemurafenib","volume":"127","author":"Dietrich","year":"2016","journal-title":"Blood"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1002\/ajh.25653","article-title":"Hairy Cell Leukemia: 2020 Update on Diagnosis, Risk Stratification, and Treatment","volume":"94","author":"Maitre","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_138","doi-asserted-by":"crossref","unstructured":"Robak, T., Janus, A., Jamroziak, K., Tiacci, E., and Kreitman, R.J. (2021). Vemurafenib and Rituximab in Patients with Hairy Cell Leukemia Previously Treated with Moxetumomab Pasudotox. J. Clin. Med., 10.","DOI":"10.20944\/preprints202106.0092.v1"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2909","DOI":"10.1002\/cncr.29487","article-title":"Characteristics of Primary Splenic Diffuse Large B-Cell Lymphoma and Role of Splenectomy in Improving Survival","volume":"121","author":"Bairey","year":"2015","journal-title":"Cancer"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/bjh.14736","article-title":"Clinicopathological Analysis of Primary Splenic Diffuse Large B-Cell Lymphoma","volume":"178","author":"Shimono","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1016\/S0140-6736(19)33008-9","article-title":"Four versus Six Cycles of CHOP Chemotherapy in Combination with Six Applications of Rituximab in Patients with Aggressive B-Cell Lymphoma with Favourable Prognosis (FLYER): A Randomised, Phase 3, Non-Inferiority Trial","volume":"394","author":"Poeschel","year":"2019","journal-title":"Lancet"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Bologna, S., Vander Borght, T., Briere, J., Ribrag, V., Damaj, G.L., Thieblemont, C., Feugier, P., Peyrade, F., Lebras, L., and Coso, D. (2021). Early Positron Emission Tomography Response-adapted Treatment in Locallized Diffuse Large B-Cell Lymphoma (AAIPI = 0): Results of The Phase 3 LYSA LNH 09-1B Trial. Hematol. Oncol., 39.","DOI":"10.1002\/hon.5_2879"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1634\/theoncologist.11-4-384","article-title":"T-Cell\/Histiocyte-Rich B-Cell Lymphoma: Biology, Diagnosis, and Management","volume":"11","author":"Abramson","year":"2006","journal-title":"Oncologist"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1038\/3880651","article-title":"CD5+ T-Cell\/Histiocyte-Rich Large B-Cell Lymphoma","volume":"15","author":"Chang","year":"2002","journal-title":"Mod. Pathol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1007\/s00428-011-1165-z","article-title":"T Cell\/Histiocyte-Rich Large B-Cell Lymphoma: An Update on Its Biology and Classification","volume":"459","author":"Tousseyn","year":"2011","journal-title":"Virchows Arch."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1182\/blood-2017-04-737445","article-title":"Intravascular Large B-Cell Lymphoma: A Chameleon with Multiple Faces and Many Masks","volume":"132","author":"Ponzoni","year":"2018","journal-title":"Blood"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"3168","DOI":"10.1200\/JCO.2006.08.2313","article-title":"Definition, Diagnosis, and Management of Intravascular Large B-Cell Lymphoma: Proposals and Perspectives from an International Consensus Meeting","volume":"25","author":"Ponzoni","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S1470-2045(20)30059-0","article-title":"Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone Combined with High-Dose Methotrexate plus Intrathecal Chemotherapy for Newly Diagnosed Intravascular Large B-Cell Lymphoma (PRIMEUR-IVL): A Multicentre, Single-Arm, Phase 2 Trial","volume":"21","author":"Shimada","year":"2020","journal-title":"Lancet Oncol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"4302","DOI":"10.1200\/JCO.20.02287","article-title":"High-Risk Mantle Cell Lymphoma: Definition, Current Challenges, and Management","volume":"38","author":"Jain","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/6\/390\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:28:54Z","timestamp":1760167734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/28\/6\/390"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,11]]},"references-count":149,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["curroncol28060390"],"URL":"https:\/\/doi.org\/10.3390\/curroncol28060390","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,11]]}}}